Floatz logo

MVF-HER-2 (266-296)

HER2-positive Gastric Cancer

Pravin T.P KaumayaPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

282 Active assets in the HER2-positive Gastric Cancer cohort.

Asset / SponsorPhaseRating
Rivoceranib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 4BBB
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 4BB
Eloxatin
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
Pembrolizumab
Eikon Therapeutics
Phase 3BB
Epirubicin
Rondo Therapeutics
Phase 3BB

View all 50 →

Same molecule, other indications

MVF-HER-2 (266-296) is also rated in:

EGFR OverexpressionDormant
CC
Indicative ·
43 / 100
View asset →
breast cancerDormant
C
Indicative ·
39 / 100
View asset →
HER2 positive breast carcinomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →